4th Quarter - Report

CAPITOL HILL CONSULTING GROUP for ENDO PHARMACEUTICALS

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
BILL K BREWSTER —
DAVID JORY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

Ensuring Safe Access to Prescription Medication Act of 2014 S.2825

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
BILL K BREWSTER —
DAVID JORY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2825 (113th)

Health Issues HCR

general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimilars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013; Able Act H.R. 647; Medicaid Generic Drug Price Fairness Act H.R.5748, S.2984

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
BILL K BREWSTER —
DAVID JORY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 647 (113th), S. 2984 (113th), H.R. 5748 (113th), H.R. 486 (113th)

Taxation/Internal Revenue Code TAX

Medical Device Tax Repeal; Stop Corporate Inversions Act S. 2360, H.R. 4679; issues relating to incentive for life sciences research' Protect Medical Innovation Act of 2013 S.232, H.R.523

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
BILL K BREWSTER —
DAVID JORY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 523 (113th), S. 232 (113th), H.R. 4679 (113th), S. 2360 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.